A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Last updated: January 6, 2026
Sponsor: Tris Pharma, Inc.
Overall Status: Completed

Phase

3

Condition

Acute Pain

Pain

Treatment

Cebranopadol

Placebo

Oxycodone IR

Clinical Study ID

NCT06423703
TRN-228-302
  • Ages 18-75
  • All Genders

Study Summary

The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.

Eligibility Criteria

Inclusion

Key Inclusion Criteria Before Surgery:

  • Scheduled to undergo primary unilateral bunionectomy with first metatarsal osteotomyand internal fixation with no collateral procedures, using anesthesiologic andsurgical procedures planned.

  • Must be able to adhere to the visit schedule, complete all study assessments andprotocol requirements, including self-reported questionnaires.

Key Exclusion Criteria Before Surgery:

  • Any clinically significant disease, medical condition, or laboratory finding that inthe investigator's opinion may interfere with the study procedures or dataintegrity, or compromise the safety of the subject.

  • Secondary (i.e., unrelated to bunion) current painful condition that could confoundthe interpretation of efficacy, safety, or tolerability data in the study, in theopinion of the investigator.

  • Subjects who require any analgesic for secondary (i.e., unrelated to bunion) painfulcondition that might impact the subject's ability to properly assess theirpostoperative pain, or that may require treatment during the Treatment Phase.

  • History of allergy or hypersensitivity to any opioid analgesics, anesthetics,ibuprofen, or other NSAIDs.

Exclusion

Immediate Postoperative Exclusion Criteria:

  • Surgical, postsurgical, or anesthetic complication that could confound theinterpretation of efficacy, safety, or tolerability data in the study.

  • Deviation from the surgical, postsurgical, or anesthetic protocol that couldconfound the interpretation of efficacy, safety, or tolerability data in the study.

  • Evidence of hemodynamic instability or respiratory insufficiency.

Study Design

Total Participants: 240
Treatment Group(s): 3
Primary Treatment: Cebranopadol
Phase: 3
Study Start date:
July 18, 2024
Estimated Completion Date:
January 31, 2025

Study Description

This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled parallel-group study to evaluate the efficacy and safety of cebranopadol in the treatment of postoperative pain following primary unilateral bunionectomy with first metatarsal osteotomy. The study will be conducted in 3 phases: Screening, Treatment, and Follow-up.

Connect with a study center

  • ALLEVIATE 2 Site 001108

    Sheffield, Alabama 35660
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001108

    Sheffield 4089536, Alabama 4829764 35660
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001106

    Little Rock, Arkansas 72211
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001106

    Little Rock 4119403, Arkansas 4099753 72211
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001103

    Tampa, Florida 33613
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001103

    Tampa 4174757, Florida 4155751 33613
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001102

    Atlanta, Georgia 30331
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001102

    Atlanta 4180439, Georgia 4197000 30331
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001107

    Overland Park, Kansas 66212
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001107

    Overland Park 4276873, Kansas 4273857 66212
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001105

    Pasadena, Maryland 21122
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001105

    Pasadena 4364990, Maryland 4361885 21122
    United States

    Site Not Available

  • Alleviate 2 001113

    Houston, Texas 77043
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001104

    McAllen, Texas 78501
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001111

    San Antonio, Texas 78240
    United States

    Site Not Available

  • Alleviate 2 001113

    Houston 4699066, Texas 4736286 77043
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001104

    McAllen 4709796, Texas 4736286 78501
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001111

    San Antonio 4726206, Texas 4736286 78240
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001101

    Salt Lake City, Utah 84107
    United States

    Site Not Available

  • ALLEVIATE 2 Site 001101

    Salt Lake City 5780993, Utah 5549030 84107
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.